Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to...

Area of Science:

• Biochemistry
• Virology
• Drug Discovery

Background:

• Human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) is a critical target for AIDS therapy.
• Nonnucleoside analog compounds, including nevirapine, effectively inhibit HIV-1 RT.
• Understanding the structural basis of inhibitor resistance is vital for developing new antiviral strategies.

Purpose of the Study:

• To investigate the role of specific amino acid residues in HIV-1 RT sensitivity to nonnucleoside analog inhibitors.
• To determine why HIV-2 RT is resistant to these compounds.

Main Methods:

• Site-directed mutagenesis was used to substitute amino acid residues in HIV-1 and HIV-2 RT.
• Enzyme activity assays were performed to assess inhibitor sensitivity.
• Comparison of amino acid sequences between HIV-1 and HIV-2 RT.

Main Results:

• Tyrosine residues at positions 181 and 188 in HIV-1 RT are essential for sensitivity to nonnucleoside inhibitors.
• HIV-2 RT, lacking tyrosines at these positions, exhibits resistance to these inhibitors.
• Mutating HIV-2 RT to mimic HIV-1 RT at positions 181 or 188 confers resistance, while substituting a region from HIV-1 RT confers sensitivity.

Conclusions:

• The presence of tyrosine residues at positions 181 and 188 is a key determinant of HIV-1 RT sensitivity to nonnucleoside analog inhibitors.
• Structural variations in RT between HIV-1 and HIV-2 contribute to differential drug responses.
• These findings provide insights for designing novel HIV-1 RT inhibitors with improved efficacy and reduced resistance.